Pharmaceutical

Acerus Pharmaceuticals (TSX:ASP) announced today that Hyundai Pharm Co., Ltd. (Hyundai), Acerus’ licensee, reported that South Korea’s Ministry of Food and Drug Safety (MFDS) has approved NATESTO® for the treatment of hypogonadism. As quoted in the press release: “Acerus is very pleased by the speed with which Hyundai has been able to prepare the dossier and …

Acerus Pharmaceuticals (TSX:ASP) announced today that Hyundai Pharm Co., Ltd. (Hyundai), Acerus’ licensee, reported that South Korea’s Ministry of Food and Drug Safety (MFDS) has approved NATESTO® for the treatment of hypogonadism.

As quoted in the press release:

“Acerus is very pleased by the speed with which Hyundai has been able to prepare the dossier and collaborate with the MFDS to obtain a notice of approval for NATESTO® in South Korea. This approval marks an important milestone in establishing NATESTO®globally as this is the first regulatory approval outside of North America,” said Ed Gudaitis, President and Chief Executive Officer of Acerus Pharmaceuticals.

Acerus will receive a regulatory milestone payment linked to the regulatory approval. Additionally, Acerus will oversee ongoing manufacturing of NATESTO® and receive a supply price for product. Commercial launch is planned in Q4 2018.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20197.61+15.69
TSXV702.09-3.49
DOW31261.90+8.77
S&P 5003901.36+0.57
NASD11354.62-33.88
ASX7145.60+81.10

COMMODITIES

Commodities
Gold1846.53+0.13
Silver21.75+0.03
Copper4.30+0.02
Palladium1968.65+11.53
Platinum957.67+3.19
Oil110.35-1.86
Heating Oil3.62-0.05
Natural Gas8.06-0.25

DOWNLOAD FREE REPORTS

×